3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
6
Breast Neoplasms
6
Endometrial Neoplasms
4
Fallopian Tube Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasms by Site
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Digestive System Neoplasms
1
Carcinosarcoma
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
Psychiatric Rehabilitation
4
Flow Cytometry
3
Early Intervention, Educational
3
Surveys and Questionnaires
2
Methylprednisolone
2
Methods
2
Melphalan
2
Immunologic Techniques
2
Gene Expression Profiling
2
Cyclophosphamide
2
Counseling
2
Bupropion
2
Blood Specimen Collection
2
Azacitidine
2
Alemtuzumab
2
tanespimycin
1
sargramostim
1
ruxolitinib
1
rucaparib
1
ribociclib
1
pembrolizumab
1
liposomal doxorubicin
1
ixabepilone
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
cc-486
1
aldesleukin
1
abiraterone
1
Zoledronic Acid
1
Zinc Oxide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
ribociclib
×
Gynecologic
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts